MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Entry into a Material Definitive Agreement

Item1.01

On January27, 2017, Microbot Medical Inc. (the Company) entered
into a Contract Research Agreement (the Agreement) with The
Washington University (Washington U.), to which the parties will
collaborate to determine the effectiveness of the Companys
self-cleaning shunt, a device designed to prevent obstruction in
the cerebrospinal fluid catheters implanted in the ventricle of
the brain of patients who suffer from hydrocephalus and Normal
Pressure Hydrocephalus.

The initial research to be performed by Washington U. is expected
to be completed within 6 months, with a comprehensive study to
follow and be completed in 2018.

The cost of these studies, to be paid by the Company, is expected
to be approximately $130,000.

to the Agreement, all rights, title and interest in the data,
information and results obtained or arrived at by Washington U.
in the performance of its services under the Agreement, as well
as any patentable inventions obtained or arrived at in the
performance of such services, will be jointly owned by the
Company and Washington U., and each will have full right to
practice and grant licenses in joint inventions. Additionally,
Washington U. granted to the Company (a)a non-exclusive,
worldwide, royalty-free, fully paid-up, perpetual and irrevocable
license to use and practice patentable inventions (other than
joint inventions and improvements to Washington U.s animal
models) obtained or arrived at by Washington U. in the provision
of its services under the Agreement (University Inventions) with
respect to the self-cleaning shunt and (b)an exclusive option to
obtain an exclusive worldwide license in University Inventions,
on terms to be negotiated between the parties.

The Agreement contains customary confidentiality provisions and
an indemnity in favor of Washington U.

The Agreement shall continue for a period of two years, subject
to early termination for breach or if the principal investigators
at Washington U. cease to supervise the services.

The foregoing summary of the terms of the Agreement is subject
to, and qualified in its entirety by, the full text of the
Agreement, which will be filed with the Companys Annual Report on
Form 10-K for the fiscal year ended December31, 2016.

On January30, 2017, the Company issued a press release announcing
the execution of the Agreement. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated herein by reference.

About MICROBOT MEDICAL INC. (NASDAQ:MBOT)

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

MICROBOT MEDICAL INC. (NASDAQ:MBOT) Recent Trading Information

MICROBOT MEDICAL INC. (NASDAQ:MBOT) closed its last trading session 00.00 at 5.05 with 33,882 shares trading hands.